Q-omics provides the consensus-scored LRRC28 profile across patient tissues and cancer cell-line models. LRRC28 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LRRC28 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, LRRC28 RNA expression shows 19,341 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where LRRC28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC28 survival associations across molecular data types. LRRC28 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC28 RNA expression–survival associations across cancer types. High LRRC28 expression shows unfavorable associations in LGG, ACC, STAD and LIHC, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LRRC28 RNA expression.
This table summarizes LRRC28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC28 shows lower tumor expression in KICH, THCA, KIRC, KIRP and BRCA and higher tumor expression in HNSC. The KICH box plot shows higher LRRC28 RNA expression in normal versus tumor tissue (log2 FC = −1.468, t-test p < 0.001).
This table shows molecular features associated with LRRC28 in patient tissues and cancer cell lines. In patient samples, LRRC28 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
